ReviewTherapeutic advances in musculoskeletal disease2016
Cardiovascular risk in rheumatoid arthritis: assessment, management and next steps.
Review in Therapeutic advances in musculoskeletal disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 79 citations in OpenAlex.
- Trial
- Bone Health in Rheumatoid Arthritis: An Update.Current rheumatology reports · 2026Review
- Sodium-Glucose Co-Transporter 2 Inhibitor Use and Risk of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis and Type 2 Diabetes: A Retrospective Observational Cohort Study Using Real-World Data.Journal of clinical medicine research · 2026Article
- The prevalence of coronary artery disease in rheumatoid arthritis patients in Palestine: a cross-sectional study.BMC rheumatology · 2026Article
- Effect of Structured Exercise on Blood Pressure in Patients With Rheumatoid Arthritis: A Systematic Review.Cureus · 2025Review
- Periodontitis, Dyslipidemia and Rheumatoid Arthritis: An Additive Model of Cardiovascular Risk.Journal of clinical medicine · 2025Article
- Article
- The comparative prevalence of comorbidities across rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis.Rheumatology advances in practice · 2025Article
- Interplay of rheumatoid arthritis and cardiovascular disease: Insights and prospects.SAGE open medicine · 2025Review
- [Small Molecule Therapy for Inflammatory Bowel Disease: JAK Inhibitors and S1PR Modulators].The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2024Review
- Cardiovascular Risk Management In Patients With Rheumatoid Arthritis: A Systematic Review.Cureus · 2024Review
- Rheumatoid arthritis, cardiometabolic comorbidities, and related conditions: need to take action.Frontiers in medicine · 2024Review
- Effect of Filgotinib on Body Mass Index (BMI) and Effect of Baseline BMI on the Efficacy and Safety of Filgotinib in Rheumatoid Arthritis.Rheumatology and therapy · 2023Article
- Pathogenesis of Extraarticular Manifestations in Rheumatoid Arthritis-A Comprehensive Review.Biomedicines · 2023Review
- The Hypertriglyceridemic Waist Phenotype Is Associated with Several Cardiovascular Risk Factors in Women with Rheumatoid Arthritis.Healthcare (Basel, Switzerland) · 2023Article
- JAK Inhibition in Patients with Rheumatoid Arthritis: Haemodynamic Effects and Impact on Micro- and Macrovascular Function. Study Design and Rationale.Mediterranean journal of rheumatology · 2022Article
- Subclinical Atherosclerosis Measure by Carotid Ultrasound and Inflammatory Activity in Patients with Rheumatoid Arthritis and Spondylarthritis.Journal of clinical medicine · 2022Article
- Premature stroke and cardiovascular risk in primary Sjögren's syndrome.Frontiers in cardiovascular medicine · 2022Article
- Association between Carotid Intima-Media Thickness and the Use of Biological or Small Molecule Therapies in Patients with Rheumatoid Arthritis.Diagnostics (Basel, Switzerland) · 2021Article
- Ischemic Heart Disease and Rheumatoid Arthritis-Two Conditions, the Same Background.Life (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is associated with increased cardiovascular (CV) morbidity and mortality which cannot be fully explained by traditional CV risk factors; cumulative inflammatory burden and antirheumatic medication-related cardiotoxicity seem to be important contributors. Despite the acknowledgment and appreciation of CV disease burden in RA, optimal management of individuals with RA represents a challenging task which remains suboptimal. To address this need, the European League Against Rheumatism (EULAR) published recommendations suggesting the adaptation of traditional risk scores by using a multiplication factor of 1.5 if two of three specific criteria are fulfilled. Such guidance requires proper coordination of several medical specialties, including general practitioners, rheumatologists, cardiologists, exercise physiologists and psychologists to achieve a desirable result. Tight control of disease activity, management of traditional risk factors and lifestyle modification represent, amongst others, the most important steps in improving CV disease outcomes in RA patients. Rather than enumerating studies and guidelines, this review attempts to critically appraise current literature, highlighting future perspectives of CV risk management in RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.